Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
Status:
Withdrawn
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to test the safety and efficacy of BL-8040 (a CXCR4 antagonist) in
improving the response to imatinib in CML patients not achieving an optimal response with
imatinib alone.